Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Avelumab vs Chemotherapy in Third-line Gastric or GEJ Adenocarcinoma
jRCT2080223494Phase 3Completed
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of avelumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms). Started Mar 2017; status: completed.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223494.